ZD 2486

Drug Profile

ZD 2486

Latest Information Update: 07 Apr 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antiplatelets; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unstable angina pectoris

Most Recent Events

  • 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
  • 08 Sep 1998 Discontinued-II for Unstable angina pectoris in United Kingdom (IV)
  • 08 Sep 1998 Discontinued-II for Unstable angina pectoris in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top